We’re dedicated to breaking boundaries through clinical studies and to finding new and improved ways to treat cancer that deliver better life outcomes for our patients
A Multicenter, Double-blind, Placebo-controlled, Adaptive Phase 3 Trial of POL-103A Polyvalent Melanoma Vaccine in Post-resection Melanoma Patients With a High Risk of Recurrence
Ongoing 2020 North Florida / Jacksonville: Rhonda Calhoun (904) 427-1217
Cancer
MROQC
MROQC
Ongoing 2020 Michigan: Maria Pappas (248) 553-0606
Cancer
CTP-2
Intensity Modulated Radiation Therapy followed by Cesium‐131 Brachytherapy for Intermediate and High Risk Localized Prostate Cancer.